Karyopharm Therapeutics Inc KPTI

NAS: KPTI | ISIN: US48576U1060   22:00
1,130 USD (+3,67%)
(+3,67%)   22:00

8 mei 2024 · Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

8 mei 2024 · Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 · Persbericht

8 mei 2024 · Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

2 mei 2024 · Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 · Persbericht

1 mei 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

24 april 2024 · Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting · Persbericht

1 april 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 maart 2024 · Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences · Persbericht

1 maart 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 februari 2024 · Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress · Persbericht

22 februari 2024 · Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 · Persbericht

1 februari 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 januari 2024 · Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives · Persbericht

3 januari 2024 · Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

2 januari 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

11 december 2023 · Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1) · Persbericht

1 december 2023 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2023 · Karyopharm to Participate at Upcoming Investor Conferences · Persbericht

6 november 2023 · Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study · Persbericht

2 november 2023 · Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH) · Persbericht

Mijn selecties